CD19 CAR NK-92 Cells With CD16 for Targeted Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NK cell therapies for cancer treatment are limited to autologous contexts and face challenges due to the variability in cytolytic activity among NK cells, and there is a need for more effective targeted therapies against CD19-expressing malignancies.
Innovation Solution
Engineering NK-92® cells to express a CD19 chimeric antigen receptor (CAR) and a Fc receptor, such as CD16, along with IL-2, to enhance their cytotoxicity and ADCC activity, enabling them to target and kill CD19-positive tumor cells effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous NK cells are used for therapy, then the treatment is limited to autologous contexts and requires cell isolation and expansion, but the variability in cytolytic activity among NK cells reduces therapeutic effectiveness
Solution Approach 1:
The patent modifies key parameters of NK cells by engineering them to express specific receptors (CD16 Fc receptor and CD19 CAR). This parameter change transforms variable autologous NK cells into standardized, high-performance therapeutic cells with enhanced cytolytic activity and targeted recognition capability, resolving the contradiction between reliability and adaptability
Solution Approach 2:
The engineered NK cells are designed to be self-sufficient by incorporating IL-2 secretion capability, allowing them to autonomously produce their own growth and activation signals. This self-service mechanism eliminates dependency on external cytokine support and ensures consistent therapeutic performance regardless of individual patient variability
2Reliability
If NK-92® cells are engineered to express multiple transgenes (CD19 CAR, Fc receptor, IL-2), then cytotoxicity and ADCC activity are enhanced, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent combines multiple functional transgenes (CD19 CAR, Fc receptor, and IL-2) into a single multi-cistronic construct. This merging approach delivers multiple therapeutic functions simultaneously while simplifying the manufacturing process by requiring only one transfection event and one viral vector preparation, rather than multiple separate transfections
Solution Approach 2:
The engineered NK-92® cells achieve multi-functionality by expressing CD19 CAR for targeted recognition, Fc receptor for ADCC enhancement, and IL-2 for autonomous growth. This universal design creates a single cell product that performs multiple therapeutic functions, reducing the need for combination therapies and simplifying clinical implementation
3Productivity
If higher effector-to-target ratios are used to improve killing efficacy, then more NK cells are required for treatment, but the cost and complexity of cell production increase
Solution Approach 1:
The patent changes the functional parameters of NK cells through receptor engineering, transforming them from standard cytotoxic cells into high-performance killers with enhanced cytolytic activity and ADCC capability. This parameter change allows achieving higher killing efficacy at lower cell doses, reducing the quantity of cells required for effective treatment
Data Source
AI summary
Provided herein are compositions of NK-92® cells that express a CD19 CAR, CD16 and IL2, and the method of using these cells to and treat cancer in a patient.